Iran Press/ America: The US president plans to speed up the process of approving an experimental coronavirus vaccine being developed in Britain to be used before the US presidential election in November.
In a bid to secure a coronavirus vaccine before November 3, Trump wants the US Food and Drug Administration to grant emergency use authorization to the vaccine being developed by Oxford University in the weeks leading up to the election, even if it does not yet have full regulatory approval, the Financial Times reports, citing unnamed sources.
The Oxford vaccine, being developed in partnership with the pharmaceutical firm AstraZeneca, is set to be trialed on 10,000 volunteers in the coming weeks; however, US health authorities have indicated a vaccine must be successfully trialed on 30,000 volunteers to receive authorization.
Two senior figures in the Trump administration last month told House Speaker Nancy Pelosi in a meeting that the president wanted to bypass these requirements by granting the vaccine emergency use authorization, an unnamed source briefed on the meeting told the Financial Times.
214/219
Read More:
Results of human trials of Iran COVID-19 vaccine clear by November
China affirms first COVID-19 vaccine patent
Putin: First COVID-19 vaccine made in Russia approved
